RICARDO
RUIZ VILLAVERDE
Instituto de Investigación Biosanitaria de Granada
Granada, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Biosanitaria de Granada (2)
2022
-
Factors associated with adverse reactions to BNT162b2 COVID-19 vaccine in a cohort of 3969 hospital workers
Vaccines, Vol. 10, Núm. 1
-
Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
Life, Vol. 12, Núm. 11